Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699556 · ClinicalTrials.gov registry record · Phase 2
Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy
A Phase 2 study of Alcohol Drinking, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00699556: Completed Phase 2 study of Alcohol Drinking, sponsored by Yale University.
NCT00699556 is a Phase 2 study of Alcohol Drinking that has completed, run by Yale University. The registered enrollment target is 22 participants, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00699556, a Phase 2 study of Alcohol Drinking, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.
Primary Outcome
Participants are presented with alcohol beverages and allowed to drink at their leisure.
Conditions Studied
Interventions
- DRUG 21mg transdermal nicotine patch (Nicoderm CQ)
- DRUG 1mg nicotine nasal spray
- DRUG placebo nasal spray
Study Locations (1)
Connecticut
- Connecticut Mental Health Center & Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT00699556 record still lists
NCT00699556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Alcohol Drinking appearing as the primary indexed condition, and to 3 interventions - of which 21mg transdermal nicotine patch (Nicoderm CQ) is the first listed.
NCT00699556 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00699556 about?
NCT00699556 is a clinical study titled "Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy". This study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.
What is the current status of trial NCT00699556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-01. Estimated completion is 2016-11.
What conditions does trial NCT00699556 study?
This clinical trial studies the following conditions: Alcohol Drinking.
What interventions are being tested in trial NCT00699556?
The interventions under investigation include: 21mg transdermal nicotine patch (Nicoderm CQ) (DRUG), 1mg nicotine nasal spray (DRUG), placebo nasal spray (DRUG).
Who is sponsoring clinical trial NCT00699556?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00699556 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Drinking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00699556's enrollment target sits among peer trials
22 74th of 85 higher than 11 of 85 other Alcohol Drinking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Drinking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
Ketone Ester Intervention in Alcohol Use Disorder
RECRUITING · Phase 2
-
Effects Ketone Supplement and Alcohol on Brain Metabolism
RECRUITING · Phase 2
-
Effect of Nutritional Ketosis on Alcohol Metabolism
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Acute Effects of Ketone Supplement on Responses to Alcohol Challenge in Healthy Volunteers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia